BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  SpineFrontier Executives Arrested in Alleged Kickback Scheme

  Chin, 57, and Humad, 36, along with the company, were indicted on charges of paying surgeons to use their spinal implants in surgeries.

  September 8, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Could Lab-Grown Mini Brains Hold the Key to Parkinson’s Disease?

  Scientists from different agencies and research facilities have turned to laboratory manufactured human mini-brains to study the onset and progression of Parkinson’s disease.

  September 8, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Replicate Launches with $40 Million to Eliminate Drug Resistance in Cancer

  Replicate focuses on using self-replicating RNA (srRNA) to develop therapies for autoimmune and inflammatory diseases and prevent drug resistance in cancer.

  September 8, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  COVID-19 Update: Super-Immunity, Booster Shots, Mu and Moderna

  Heading into fall, with the COVID-19 pandemic surging again and researchers tracking new variants, there’s plenty of news. Here’s a look.

  September 8, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Deals

  Sanofi Enhances Transplant Portfolio with $1.9 Billion Kadmon Acquisition

  The acquisition expands Sanofi’s General Medicines core assets and highlights the addition of Rezurock (belumosudil) to its transplant portfolio.

  September 8, 2021

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Biotech Bay

  Biopharma Company Earns Fresh Funds to Push PAR Therapeutics to Clinic

  Attralus Therapeutics has had a fresh set of faces shuffling into its executive suite in the past few months. And apparently with new leadership comes new funding opportunities.

  September 8, 2021

   · 

  2 min read

   · 

  Ellen Bombela
• 

  Drug Development

  MacroGenics’ Breast Cancer Treatment Disappoints in Phase III

  The biopharmaceutical company announced the final overall survival analysis of its drug MARGENZA in SOPHIA Phase III study in adults with metastatic breast cancer.

  September 8, 2021

   · 

  2 min read

   · 

  Ellen Bombela
• 

  Pharm Country

  Lucerna is Illuminating the Mysteries of RNA to Solve Diseases

  The company aims to make RNA molecules visible and druggable – opening the door to study RNA-based diseases.

  September 8, 2021

   · 

  4 min read

   · 

  Maggie Chen
• 

  Deals

  Diaccurate Adds Merck PAM Inhibitor to Oncology/Immunology Pipeline

  French biotech Diaccurate bolstered its oncology and immunology pipeline with the acquisition of a Phase II-ready dual PAM inhibitor from Merck KGaA, Darmstadt, Germany.

  September 8, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Global Roundup: ProQR Licenses Axiomer RNA Editing Platform to Eli Lilly

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

  September 8, 2021

   · 

  5 min read

   · 

  Alex Keown